Literature DB >> 24374358

Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors.

Fatma Ilknur Cinar1, Muhammet Cinar, Sedat Yilmaz, Ismail Simsek, Hakan Erdem, Salih Pay.   

Abstract

The risk of infections and malignancies is the major area of concern with anti-tumor necrosis factor (anti-TNF) agents. The aim of this study was to investigate patients' views about their treatments and the factors that influence patients' treatment decisions concerning the use of anti-TNF-α drugs. This descriptive study was conducted in a single rheumatology unit. Patients using anti-TNF-α drugs for at least 3 months were included. Patients' thoughts and perceptions about their treatment were evaluated using a questionnaire. A total of 101 (94.1% male) patients were recruited. The patients described their feelings as hopeful, worried, happy, scared, desperate, and hopeless, with the order decreasing beginning with the first. Hope for healing and an expectation of increased quality of life were the most significant determinants for acceptance of treatment. After the drug information was given, patients described their feelings as follows: increase in anxiety, psychologically wearisome, and worrying about their condition worsening in the future. After anti-TNF-α treatment, patients described their experience as follows: "the most effective medicine that I have ever used," "it saved my life," "control procedures that were carried out before the treatment and once every 3 months after the treatment were essential," "I feel myself safe with these controls," and "I advised other people." This study, to our knowledge, is the first to evaluate the attitudes of patients concerning anti-TNF-α drugs from the stage of informed consent to the post-experience stage. We found that standard consent forms caused an increase in the level of anxiety among new users of anti-TNF-α drugs, although the aim was the exact opposite. The reasons for acceptance were the hope for healing, reliance on physicians, and advice of other patients. Most patients accepted follow-up control procedures, which aimed to diagnose adverse effects early.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24374358     DOI: 10.1007/s00296-013-2931-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

2.  Fatigue in ankylosing spondylitis: causes, consequences and self-management.

Authors:  Wendy Farren; Lynne Goodacre; Mark Stigant
Journal:  Musculoskeletal Care       Date:  2012-07-24

3.  Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis.

Authors:  Ozlem Baysal; Bekir Durmuş; Yüksel Ersoy; Zuhal Altay; Kazım Senel; Kemal Nas; Mahir Uğur; Arzu Kaya; Ali Gür; Akın Erdal; Ozge Ardıçoğlu; Ibrahim Tekeoğlu; Remzi Cevik; Kadir Yıldırım; Ayhan Kamanlı; Ayşegül Jale Saraç; Saliha Karatay; Salih Ozgocmen
Journal:  Rheumatol Int       Date:  2010-03-10       Impact factor: 2.631

4.  Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures.

Authors:  Hanne Dagfinrud; Nina K Vollestad; Jon H Loge; Tore K Kvien; Anne Marit Mengshoel
Journal:  Arthritis Rheum       Date:  2005-02-15

5.  Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis.

Authors:  Rafael Ariza-Ariza; Blanca Hernández-Cruz; Federico Navarro-Sarabia
Journal:  Arthritis Rheum       Date:  2003-08-15

6.  Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Paul Wordsworth; Eduardo Loza Cortina; Joachim Sieper; Martina Kron; Roberto Carcereri-De-Prati; Hartmut Kupper; Sonja Kary
Journal:  J Rheumatol       Date:  2009-02-27       Impact factor: 4.666

7.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

8.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

Review 10.  Nursing interventions for patients with chronic conditions.

Authors:  Liv Merete Holm Frich
Journal:  J Adv Nurs       Date:  2003-10       Impact factor: 3.187

View more
  6 in total

1.  Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort.

Authors:  Jorit J L Meesters; Ingemar F Petersson; Stefan Bergman; Emma Haglund; Lennart T H Jacobsson; Ann Bremander
Journal:  Clin Rheumatol       Date:  2014-06-08       Impact factor: 2.980

Review 2.  Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

Authors:  Andrew Keat; Alexander N Bennett; Karl Gaffney; Helena Marzo-Ortega; Raj Sengupta; Tamara Everiss
Journal:  Rheumatol Int       Date:  2016-12-29       Impact factor: 2.631

3.  Self-Reported Medication Adherence in Patients With Ankylosing Spondylitis: The Role of Illness Perception and Medication Beliefs.

Authors:  Sena Tolu; Aylin Rezvani; İlhan Karacan; Derya Bugdayci; Habib Can Küçük; Ömer Faruk Bucak; Teoman Aydin
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

4.  Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry.

Authors:  William Benjamin Nowell; Kelly Gavigan; Theresa Hunter; William N Malatestinic; Rebecca J Bolce; Jeffrey R Lisse; Carol Himelein; Jeffrey R Curtis; Jessica A Walsh
Journal:  ACR Open Rheumatol       Date:  2021-11-10

5.  Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea.

Authors:  In Ah Choi; Ji Hyoun Kim; Sung Hae Chang; Ran Song; You-Jung Ha; Hye Won Kim; Jeong Seok Lee; Byoongyong Choi; Yoon-Jeong Oh; Ki Won Moon
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.472

6.  Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey.

Authors:  Woojin Joo; Christopher V Almario; Mariko Ishimori; Yujin Park; Alma Jusufagic; Benjamin Noah; Lianne S Gensler; R Swamy Venuturupalli; Jonathan Kay; Michael H Weisman; Brennan M R Spiegel
Journal:  ACR Open Rheumatol       Date:  2020-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.